Comparison
DSIP vs. Liraglutide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Metabolic
CAS no.
62568-57-4
204656-20-2
Molecular weight
848.81 g/mol
3751 g/mol
Half-life
0.1 h
13 h
Sequence
Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-GluHAEGTFTSDVSSYLEGQAAKEFIAWLVRGRGMechanism of action
DSIP
DSIP was described in 1977 by the Schoenenberger-Monnier group in Basel as a blood-borne substance reported to induce EEG changes similar to delta sleep in animal models. The exact mechanism remains undefined to this day: no defined receptor, proposed modulation of opioid, GABAergic and glutamatergic systems. Most mechanistic findings stem from preclinical studies of the 1980s and 1990s and were later subjected to contested replication attempts.
Liraglutide
Liraglutide is a synthetic GLP-1 analog with 97% sequence identity to human GLP-1. A fatty-acid side chain (C16) on Lys-26 reversibly binds serum albumin and protects against DPP-4 degradation. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon secretion, delays gastric emptying and modulates central satiety.
Evidence base
Highest evidence
Human trial
Human RCT
Studies
4
5
of which in humans
1
4
Effects recorded
3
3
Open conflicts
1
0
Documented adverse events
1
1